Puma Biotechnology Announces 2026 Annual Meeting Results and Rejection of CEO Warrant Extension

On June 11, 2026, Puma Biotechnology, Inc. held its 2026 Annual Meeting of Stockholders. Stockholders elected eight directors to serve one-year terms: Alan H. Auerbach, Alessandra Cesano, Allison Dorval, Michael P. Miller, Jay M. Moyes, Adrian M. Senderowicz, Brian Stuglik, and Troy E. Wilson. Additionally, stockholders ratified the selection of KPMG LLP as the company\\'s independent registered accounting firm for the fiscal year ending December 31, 2026, and approved, on an advisory basis, the compensation of the company\\'s named executive officers. Notably, stockholders did not approve a proposal to amend and extend the term of a warrant held by CEO Alan H. Auerbach. The warrant, which allows for the purchase of 2,116,250 shares at $16.00 per share, was sought to be extended from October 4, 2026, to October 4, 2028. The proposal failed with 19,596,238 votes against versus 18,234,150 votes for.